Novartis spends $500M to acquire DTxPharma, boost neuroscience capabilities
The top asset Novartis is picking up through the deal is DtX Pharma’s Fatty Acid Ligand Conjugated OligoNucleotide (FALCON) platform.
Source: mmm-online.com
Page 5 - Dtx Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Dtx Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Dtx Pharma Today - Breaking & Trending Today
Novartis builds on neuroscience pipeline and xRNA platform capabilities with acquisition of DTx Pharma
DTx Pharma is a preclinical stage biotechnology company that focuses on developing siRNA therapies for neuroscience indications, leveraging its proprietary…
Source: biztoc.com
Progressive Supranuclear Palsy Market Growing at a CAGR of 27.7% During the Study Period (2019-2032), Assesses DelveInsight
/PRNewswire/ -- DelveInsight's Progressive Supranuclear Palsy Market Insights report includes a comprehensive understanding of current treatment practices,...
Source: prnewswire.com
AI Accurately Interprets EEGs; Migraine Drugs Go Head-to-Head; A Nod to Oliver Sacks
News and commentary from the world of neurology and neuroscience
Source: medpagetoday.com